Cur gy: ren lo t o R t e a s e Boonsopon et al., Rheumatology (Sunnyvale) m a u r c e h h 2015, 5:1 R Rheumatology: Current Research DOI: 10.4172/2161-1149.1000150 ISSN: 2161-1149 Review Article Open Access Ocular Manifestations in Systemic Lupus Erythematosus Sutasinee Boonsopon1,2, Armin Maghsoudlou1,2 and Charles Stephen Foster1,2,3* 1Massachusetts Eye Research and Surgery Institution (MERSI), Cambridge, MA, USA 2Ocular Immunology and Uveitis Foundation, USA 3Harvard Medical School, Cambridge, MA, USA *Corresponding author: Charles Stephen Foster, Massachusetts Eye Research and Surgery Institution, 355 Main Street, 8th Floor, Cambridge, MA 02142 USA, Tel: 617-621-6377; Fax: 617-494-1430; E-mail:
[email protected] Received date: February 20, 2015; Accepted date: March 24, 2015; Published date: March 30, 2015 Copyright: © 2015 Boonsopon S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease manifest with multiple organ system involvement. Even though the eye is not part of the diagnostic criteria, once it gets affected, it will alter patients’ quality of life. The purpose of this review is to point out the significance of ocular manifestations in SLE and to emphasize the importance of possible blinding complications such as peripheral ulcerative keratitis, scleritis, and SLE retinopathy/ choroidopathy. The condition can be even worse when SLE is accompanied with antiphospholipid syndrome. In addition to the disease itself, several treatment agents that are used in SLE are responsible for vision threatening conditions; thus they have to be given with caution because of potential side effects, including cataract, glaucoma, and chloroquine maculopathy.